Rare Ovarian Cancer researchers and consumers work together to produce a research paper.

Congratulations to ALL of the authors, lead author Professor Victoria White from Deakin University, Professor Peter Fuller, Associate Professor Simon Chu, Maria Alexiadia, All from the Hudson Institute of Medical Research, Professor Thomas Jobling from Monash Health, Members from the GCT Survivor Sister Facebook Group our Founder and CEO of ROC Inc Natasha Armour (from Australia), Linda Langdale (from the UK), Sue Rogers, Kaye Ackermann and Kim Eroh (all from the USA), on having your research paper published in the journal Cancer – an international interdisciplinary journal of the American Cancer Society


You should ALL feel proud of your accomplishment. Your work will contribute to the advancement of knowledge for GCT research, and will benefit many people in the future.

Patients often don’t feel heard by the medical profession, so this world-first study published in the journal Cancer listened to females living with Granulosa Cell Tumour, a rare ovarian cancer via the social media group they set up themselves.

743 members of the Facebook group GCT Survivor Sister (GCT-SS) chose to their experience of being treated for Granulosa Cell Tumours, putting the researchers in a privileged position and giving the women a chance to make a difference.

What is GCT

Granulosa Cell Tumour are rare, making up two-seven per cent of malignant ovarian cancers. They can develop at any age, even children. The condition has a high rate of recurrence and a tendency for late recurrence up to 20 years later, meaning even if surgery is effective, females live for years in constant fear that their cancer might return.  

Hudson Institute of medical research https://www.hudson.org.au/news/social-solution-rare-ovarian-cancer-insights/

Posted in Updates and tagged , , , , , , , , , , , , , , , , , , , , , , , , , , .